Shapuaisi (603168.SH) obtained the notice of approval for the clinical trial of deoxyepinephrine ketone acid solution.

The Zhitong Finance APP reports that Sagent Pharmaceuticals (603168.SH) has announced that the company has recently received the "Drug Clinical Trial Approval Letter" (Notification No.: 2025LP03018) issued by the National Medical Products Administration for the adrenaline ketone acid solution. The company plans to conduct clinical trials once the conditions are met.